Matthew John Frigault, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 46 | 2023 | 1255 | 4.910 |
Why?
|
Neurotoxicity Syndromes | 8 | 2023 | 290 | 2.130 |
Why?
|
Receptors, Antigen, T-Cell | 14 | 2023 | 2524 | 2.020 |
Why?
|
Antigens, CD19 | 15 | 2023 | 379 | 1.880 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 10 | 2024 | 1377 | 1.640 |
Why?
|
Lymphoma | 5 | 2023 | 1873 | 1.170 |
Why?
|
Lymphoma, B-Cell | 4 | 2020 | 930 | 1.130 |
Why?
|
Central Nervous System Neoplasms | 4 | 2023 | 895 | 1.080 |
Why?
|
T-Lymphocytes | 24 | 2023 | 10163 | 0.980 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.730 |
Why?
|
Hematopoietic Stem Cell Transplantation | 10 | 2023 | 5425 | 0.720 |
Why?
|
Multiple Myeloma | 8 | 2023 | 5169 | 0.670 |
Why?
|
Hematologic Neoplasms | 4 | 2022 | 1820 | 0.580 |
Why?
|
Antigens, Neoplasm | 6 | 2022 | 1983 | 0.570 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2023 | 233 | 0.530 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2022 | 1515 | 0.430 |
Why?
|
Hematologic Diseases | 2 | 2023 | 498 | 0.310 |
Why?
|
Lentivirus | 3 | 2022 | 501 | 0.300 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4664 | 0.280 |
Why?
|
Leukocytes, Mononuclear | 2 | 2022 | 1835 | 0.280 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2021 | 1379 | 0.250 |
Why?
|
Humans | 77 | 2024 | 742088 | 0.250 |
Why?
|
Acute Kidney Injury | 3 | 2022 | 1967 | 0.240 |
Why?
|
Hodgkin Disease | 2 | 2021 | 1413 | 0.220 |
Why?
|
Cytokines | 4 | 2022 | 7317 | 0.220 |
Why?
|
Genetic Engineering | 3 | 2022 | 952 | 0.220 |
Why?
|
B-Cell Maturation Antigen | 4 | 2023 | 140 | 0.220 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3130 | 0.210 |
Why?
|
Agammaglobulinemia | 1 | 2023 | 167 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3236 | 0.210 |
Why?
|
Neoplasms | 6 | 2023 | 21596 | 0.180 |
Why?
|
Blast Crisis | 1 | 2020 | 103 | 0.180 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.180 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 647 | 0.180 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 112 | 0.170 |
Why?
|
Anemia, Aplastic | 1 | 2021 | 226 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 256 | 0.170 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 221 | 0.170 |
Why?
|
Neoplasm Proteins | 2 | 2022 | 3691 | 0.170 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 3557 | 0.160 |
Why?
|
Lymphoma, Follicular | 1 | 2022 | 435 | 0.160 |
Why?
|
Biological Products | 3 | 2022 | 856 | 0.160 |
Why?
|
Graft vs Host Disease | 2 | 2022 | 2951 | 0.160 |
Why?
|
Transplantation, Autologous | 2 | 2021 | 2123 | 0.160 |
Why?
|
Transduction, Genetic | 1 | 2020 | 913 | 0.150 |
Why?
|
Antibodies, Bispecific | 1 | 2019 | 164 | 0.150 |
Why?
|
Mice, Inbred NOD | 3 | 2019 | 1875 | 0.140 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 969 | 0.140 |
Why?
|
Carcinoma, Lobular | 1 | 2021 | 484 | 0.140 |
Why?
|
Immunomodulation | 2 | 2021 | 540 | 0.140 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1581 | 0.140 |
Why?
|
Mice, SCID | 3 | 2019 | 2715 | 0.140 |
Why?
|
Respiratory Tract Infections | 1 | 2023 | 959 | 0.140 |
Why?
|
Lymphoma, T-Cell | 1 | 2018 | 299 | 0.130 |
Why?
|
Bone Marrow Transplantation | 2 | 2020 | 2763 | 0.130 |
Why?
|
Cytokine-Induced Killer Cells | 1 | 2015 | 6 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 1581 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 689 | 0.130 |
Why?
|
Lymphocytes | 1 | 2023 | 2614 | 0.130 |
Why?
|
Glioblastoma | 2 | 2019 | 3456 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1269 | 0.120 |
Why?
|
Retrospective Studies | 15 | 2023 | 77098 | 0.120 |
Why?
|
Drug Approval | 1 | 2020 | 740 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2022 | 9185 | 0.110 |
Why?
|
Bacteremia | 1 | 2020 | 962 | 0.110 |
Why?
|
Tumor Escape | 1 | 2016 | 349 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1199 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 3 | 2017 | 3770 | 0.100 |
Why?
|
Adult | 17 | 2023 | 213712 | 0.100 |
Why?
|
Aged | 12 | 2022 | 162944 | 0.100 |
Why?
|
Central Nervous System | 3 | 2023 | 1354 | 0.100 |
Why?
|
Lymphocyte Activation | 3 | 2019 | 5519 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1575 | 0.100 |
Why?
|
Chemokines | 1 | 2015 | 954 | 0.090 |
Why?
|
Syndecan-4 | 1 | 2009 | 44 | 0.090 |
Why?
|
Bone Marrow | 1 | 2020 | 2941 | 0.090 |
Why?
|
Immunophenotyping | 1 | 2015 | 1866 | 0.090 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1712 | 0.090 |
Why?
|
Middle Aged | 11 | 2022 | 213127 | 0.090 |
Why?
|
Female | 16 | 2022 | 379592 | 0.090 |
Why?
|
Th1 Cells | 1 | 2014 | 1056 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2023 | 62966 | 0.080 |
Why?
|
Terminal Care | 1 | 2021 | 1688 | 0.080 |
Why?
|
T-Cell Antigen Receptor Specificity | 2 | 2019 | 87 | 0.080 |
Why?
|
Male | 15 | 2022 | 349538 | 0.080 |
Why?
|
Immunotherapy | 2 | 2020 | 4414 | 0.080 |
Why?
|
Interleukin-2 | 1 | 2015 | 1887 | 0.080 |
Why?
|
Th17 Cells | 1 | 2014 | 765 | 0.080 |
Why?
|
Troponin | 2 | 2023 | 524 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2723 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13256 | 0.070 |
Why?
|
Young Adult | 7 | 2021 | 56350 | 0.070 |
Why?
|
C-Reactive Protein | 3 | 2023 | 3766 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3497 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5163 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11001 | 0.070 |
Why?
|
Cyclophosphamide | 2 | 2023 | 2236 | 0.070 |
Why?
|
Genetic Vectors | 1 | 2015 | 3420 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2024 | 39004 | 0.060 |
Why?
|
HIV Infections | 2 | 2022 | 16678 | 0.060 |
Why?
|
Mechanotransduction, Cellular | 1 | 2009 | 541 | 0.060 |
Why?
|
HIV-1 | 1 | 2022 | 6934 | 0.060 |
Why?
|
Disease Management | 3 | 2020 | 2450 | 0.060 |
Why?
|
Animals | 10 | 2019 | 168561 | 0.060 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 15108 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8077 | 0.060 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3564 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2019 | 10472 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5171 | 0.060 |
Why?
|
Mutation | 3 | 2022 | 29717 | 0.050 |
Why?
|
United States | 4 | 2023 | 69693 | 0.050 |
Why?
|
Bone Marrow Examination | 1 | 2021 | 157 | 0.050 |
Why?
|
Sickle Cell Trait | 1 | 2021 | 81 | 0.050 |
Why?
|
Prognosis | 4 | 2023 | 29010 | 0.050 |
Why?
|
Epistaxis | 1 | 2021 | 111 | 0.050 |
Why?
|
Histiocytes | 1 | 2021 | 103 | 0.050 |
Why?
|
Oropharynx | 1 | 2021 | 127 | 0.050 |
Why?
|
Purpura | 1 | 2021 | 122 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13655 | 0.050 |
Why?
|
Pyrazoles | 2 | 2021 | 1970 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8328 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2020 | 132 | 0.040 |
Why?
|
Pharyngitis | 1 | 2021 | 215 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2022 | 608 | 0.040 |
Why?
|
Certification | 1 | 2023 | 423 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 10856 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2022 | 558 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 346 | 0.040 |
Why?
|
Pyrimidines | 2 | 2021 | 2933 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2020 | 57683 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8829 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 314 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4823 | 0.040 |
Why?
|
Electroencephalography | 2 | 2023 | 6142 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 355 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 590 | 0.040 |
Why?
|
Neutropenia | 1 | 2022 | 891 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2021 | 5975 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13019 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 461 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 16665 | 0.040 |
Why?
|
Mice | 6 | 2019 | 81045 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2021 | 596 | 0.040 |
Why?
|
Survival Rate | 2 | 2021 | 12773 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 952 | 0.030 |
Why?
|
Death | 1 | 2021 | 675 | 0.030 |
Why?
|
Perception | 1 | 2022 | 1188 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1368 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 638 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2013 | 0.030 |
Why?
|
Signal Transduction | 2 | 2015 | 23387 | 0.030 |
Why?
|
Adolescent | 2 | 2021 | 85649 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2615 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2014 | 88 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1402 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1274 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 2935 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 20928 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20774 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2638 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2658 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3199 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2023 | 3199 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1780 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 72145 | 0.030 |
Why?
|
Protein Binding | 2 | 2019 | 9387 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2022 | 2066 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7901 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2915 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2021 | 1618 | 0.030 |
Why?
|
K562 Cells | 1 | 2014 | 632 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2019 | 1597 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 4771 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2502 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6313 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1872 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5062 | 0.020 |
Why?
|
Survival Analysis | 1 | 2023 | 10248 | 0.020 |
Why?
|
Interleukins | 1 | 2014 | 791 | 0.020 |
Why?
|
Bioengineering | 1 | 2009 | 99 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 2978 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2009 | 821 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2017 | 1837 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8333 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2014 | 900 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4279 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2009 | 677 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4214 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9305 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3014 | 0.020 |
Why?
|
Stroke Volume | 1 | 2019 | 4983 | 0.020 |
Why?
|
Surface Properties | 1 | 2009 | 1182 | 0.020 |
Why?
|
Kidney | 1 | 2022 | 7167 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2211 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12017 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12958 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 6722 | 0.020 |
Why?
|
Fibronectins | 1 | 2009 | 723 | 0.020 |
Why?
|
Integrins | 1 | 2009 | 845 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9941 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4249 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9715 | 0.010 |
Why?
|
Depression | 1 | 2022 | 7733 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2009 | 3139 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19862 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5304 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2009 | 1525 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2019 | 11470 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7153 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 24913 | 0.010 |
Why?
|
Antibodies | 1 | 2009 | 2459 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 12730 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18006 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11472 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2014 | 14554 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 19223 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 40955 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 40450 | 0.010 |
Why?
|
Child | 1 | 2023 | 77478 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9581 | 0.010 |
Why?
|